Zinc-Modified Nanotransporter of Doxorubicine for Multi-Targeted Therapy of Prostate Cancer Cells

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60461373%3A22330%2F18%3A43915219" target="_blank" >RIV/60461373:22330/18:43915219 - isvavai.cz</a>

Result on the web

<a href="https://www.nanocon.eu/files/uploads/01/NANOCON2017_Proceedings_content.pdf" target="_blank" >https://www.nanocon.eu/files/uploads/01/NANOCON2017_Proceedings_content.pdf</a>

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Zinc-Modified Nanotransporter of Doxorubicine for Multi-Targeted Therapy of Prostate Cancer Cells

Original language description

Target therapy for oncologic diseases presents a big challenge for advance nanomedicine. In our work, we focused on multi-target approach development. Designed nanotransporter is based on polysaccharide chitosan which allows formation of nanoparticles. These nanoparticles can bind metal ions, mainly zinc (moreover, zinc stabilizes chitosan structure). The estimated zinc concentration was approximately 1 nmol/g of chitosan. In addition, chitosan nanoparticle (cage) irreversibly binds therapeutics which could be applied for targeted therapy of malignant tumours. Designed chitosan structure (LMQ, 10 g) encapsulation efficiency for doxorubicin was 50%. The pH change (tested interval 5 - 8) caused 20% release of doxorubicin from the nanocage. The nanotransporter is orientated to cancer tissue due the fact that the malignant cells highly express metallothionein (MT). The increased affinity of MT to zinc ions causes that the nanotransporter is preferentially bound to tumour regions with a high MT concentration. Our latest experimental results showed the changes in amino acid metabolism of prostate cancer signalized by increase in the amount of amino acid sarcosine. Therefore, the chitosan-based nanotransporter was modified by anti-sarcosine antibody. The functionality of designed nanotransporter was proved by ELISA with double detection of doxorubicin using fluorescence and by peroxidase activity of ABTS substrate. In another system, magnetic separation and identification of individual components of the nanotransporter were used. The sarcosine binding activity was estimated around 50%.

Czech name

—

Czech description

—

Type

D - Article in proceedings

CEP classification

—

OECD FORD branch

21002 - Nano-processes (applications on nano-scale); (biomaterials to be 2.9)

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2018

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Article name in the collection

Nanocon 2017

ISBN

978-80-87294-81-9

ISSN

—

e-ISSN

neuvedeno

Number of pages

6

Pages from-to

531-536

Publisher name

Tanger s.r.o.

Place of publication

Ostrava

Event location

Brno

Event date

Oct 18, 2017

Type of event by nationality

WRD - Celosvětová akce

UT code for WoS article

000452823300087